The House Armed Services Cyber, Innovative Technologies, and Information Systems Subcommittee’s portion of the fiscal 2023 National Defense Authorization Act would seek to foster biotechnology that could improve the U.S. military’s effectiveness.
The mark aims to create new biomanufacturing facilities, among other steps, to help transition biotech for potential military use from the experimentation stage all the way into production.
“We are hopeful that this will provide a new and much needed capability to transition products successfully proven in the lab to the commercial scale and provide that intermediate step that is currently very difficult for a lot of technologies to bridge,” a subcommittee aide told reporters Tuesday.
